CohBar to Announce 2018 Fourth Quarter Financial Results and Host Conference Call on March 18, 2019
MENLO PARK, Calif., March 04, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that the company will release its fourth quarter 2018 financial results after the market closes on Monday, March 18, 2019. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company’s business.
Details for the Conference Call and Slide Presentation:
Date: March 18, 2019Time: 5:00 p.m. ET (2:00 p.m. PT)
-- Dial-in U.S. and Canada: (800) 289-0438 -- Dial-in International: (323) 794-2423 -- Conference ID No.: 8144256
-- Go to www.webex.com, click on the ‘Join’ button and enter meeting number 923 629 679 and Password CWBR, or -- Go to www.cohbar.com and click on Q4 2018 Shareholder Presentation at top of homepage.
We kindly request that you please call into the conference audio and log into WebEx approximately 10 minutes prior to the start time so that we can begin promptly.
An audio replay of the call will be available beginning at 8:00 p.m. Eastern Time on March 18, 2019, through 11:59 p.m. Eastern Time on April 8, 2019. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 8144256. The audio replay along with the slide presentation will also be available on the homepage at www.cohbar.com from March 18, 2019 through April 8, 2019.
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar’s founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar’s efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs.
For additional company information, please visit www.cohbar.com.
Investor and Media Contact: Jeff Biunno, CFOCohBar, Inc. (650) 446-7888 firstname.lastname@example.org
Joyce Allaire LifeSci Advisors, LLC email@example.com